Gilead signs deals with Indian cos for low-cost HIV drug

Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.

August 02, 2012 / 19:32 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Gilead Sciences Inc signed deals with three Indian companies to drive sales and reduce manufacturing costs of low-cost generic versions of its HIV drug, Emtricitabine in developing countries.

Under deals with Ranbaxy Laboratories, Strides Arcolab and Mylan Inc's India unit, Gilead will provide technology and funding to help reduce manufacturing costs of the drug, the companies said.

Gilead, which sells the drug under the Emtriva brand, is the world's largest maker of branded drugs to treat the human immunodeficiency virus -- the cause of AIDS.

first published: Aug 2, 2012 07:26 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347